Neonatal Jaundice

Neonatal jaundice is the yellow discolouration of a newborn's skin and sclerae caused by raised levels of bilirubin in the blood (hyperbilirubinaemia). It is the most common clinical condition seen in the newborn period: most cases are physiological, reflecting the normal breakdown of fetal red cells combined with an immature liver, and resolve without harm. A minority of infants develop bilirubin levels high enough to risk brain injury, which is why recognition, monitoring, and timely escalation are central to newborn care.

Definition

Neonatal jaundice is visible yellowing of the skin and sclerae in a newborn due to elevated serum bilirubin (neonatal hyperbilirubinaemia), arising in the neonatal period and ranging from benign physiological jaundice to severe hyperbilirubinaemia that can threaten the brain.

Scope

This topic covers the physiology of bilirubin metabolism in the newborn, the distinction between physiological and pathological jaundice, the recognition and monitoring of jaundice, and the rationale for the treatments used to lower bilirubin. It treats neonatal jaundice as a reference clinical topic; it describes how the condition is understood and monitored and does not provide bilirubin thresholds, dosing, or individualised treatment decisions, which follow current clinical guidelines.

Core questions

• Why are newborns predisposed to jaundice in the first days of life?
• How is physiological jaundice distinguished from pathological jaundice?
• How is jaundice recognised and monitored in the newborn?
• Why does severe hyperbilirubinaemia matter, and what is the rationale for treatment?

Key concepts

• Unconjugated (indirect) versus conjugated (direct) bilirubin
• Physiological jaundice of the newborn
• Pathological jaundice (early onset, rapid rise, prolonged)
• Haemolysis and blood-group incompatibility
• Transcutaneous and serum bilirubin measurement
• Acute bilirubin encephalopathy and kernicterus
• Phototherapy and exchange transfusion (concepts)

Mechanisms

Bilirubin is produced when haem from broken-down red cells is metabolised; it circulates as unconjugated (fat-soluble) bilirubin bound to albumin, is taken up by the liver, conjugated to a water-soluble form, and excreted in bile. Newborns are predisposed to jaundice because they have a high red-cell mass with shorter-lived fetal red cells, an immature hepatic conjugation capacity, and increased enterohepatic recirculation of bilirubin - producing the common, self-limiting physiological jaundice. Jaundice is pathological when it appears too early, rises too fast, reaches high levels, or persists, which points to causes such as haemolysis from blood-group incompatibility, infection, or other disorders. When unconjugated bilirubin rises markedly it can cross into the brain and deposit in the basal ganglia, causing acute bilirubin encephalopathy and, if untreated, the permanent injury called kernicterus. Treatments such as phototherapy (which converts bilirubin in the skin to excretable forms) and, rarely, exchange transfusion are used to lower bilirubin and prevent this neurotoxicity; specific thresholds and methods are defined by guidelines.

Clinical relevance

Because jaundice is near-universal yet occasionally dangerous, distinguishing the common benign form from the infant at risk of severe hyperbilirubinaemia is one of the defining assessment tasks of the newborn period, and nurses and midwives are central to inspection, measurement, family education, and timely referral. This entry explains the condition and its monitoring for reference; bilirubin thresholds, when to treat, and how to treat are individualised and governed by current clinical guidelines, not by this text.

Epidemiology

Visible jaundice occurs in a large proportion of newborns in the first week of life, more often and more markedly in preterm infants and in those with haemolytic conditions. Severe hyperbilirubinaemia and kernicterus are far less common, particularly where systematic bilirubin assessment and timely treatment are in place, and prevention of kernicterus is the explicit aim of structured screening and management approaches.

History

Jaundice in the newborn has been recognised for centuries, but its modern management took shape with the understanding of bilirubin neurotoxicity and the mid-twentieth-century discovery that light exposure lowers bilirubin, leading to phototherapy. Recognition of haemolytic disease of the newborn and the introduction of exchange transfusion preceded this. Structured guidance from paediatric bodies, including the American Academy of Pediatrics statements and their later revision, consolidated systematic assessment aimed at preventing kernicterus.

Debates

Universal versus selective bilirubin screening

Whether all newborns should have systematic (including pre-discharge) bilirubin measurement, rather than relying on visual assessment and risk factors, has been debated; guidance has increasingly supported structured assessment to identify infants at risk of severe hyperbilirubinaemia.

Key figures

• M. Jeffrey Maisels
• Vinod K. Bhutani

Seminal works

• aap-2004
• kemper-2022

Frequently asked questions

Is newborn jaundice usually dangerous?

No. Most newborn jaundice is physiological and resolves without harm. The purpose of monitoring is to identify the minority of infants whose bilirubin rises to levels that could be harmful so they can be assessed and treated according to clinical guidelines.

Why does very high bilirubin matter?

Markedly elevated unconjugated bilirubin can enter the brain and cause acute bilirubin encephalopathy and, if untreated, permanent injury known as kernicterus, which is why severe hyperbilirubinaemia is treated to bring levels down.